Debio 0719 is a selective inhibitor of type 1 lysophosphatidic acid receptor (LPA1) and type 3 (LPA3). LPA1 plays a key role in osteolytic bone damage induced by breast tumour metastasis. Preclinical investigations demonstrated that blockage of LPA1 by use of Debio 0719 led to a reduction in osteolytic lesions and tumour expansion.

Press Releases